Eve Health Group (EVE.AX) Stock Price

Eve Health Group Price

CLOSED
0.01
​
Market closed

Over the last 19 years Eve Health Group grew revenue by 5.2% annually, reaching 1.15 M AUD. For Eve Health Group, the net margin of -164.0% is up versus -267.4% a few years ago.

Eve Health Group stock price

Access this data via the Eulerpool API

Eve Health Group business model & stock analysis

EVE Health Group Ltd. engages in the development and provision of health and wellness solutions. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2004-04-08. The Company’s segments include Jenbrook, Meluka and Investment. The Jenbrook segment produces organic tea tree and distributes Australian botanical oils. The Meluka segment is a retail health and wellness consumer brand. The Meluka segment provides retail health and wellness consumer products, including honey. The firm owns and operates the Robyndale organic tea tree plantation in the Bungawalbin Valley in Northern New South Wales. Jenbrook farm offers products, including essential oil, dried leaf, hydrosol, and extract. Its Naturally Australian Products is a wholesaler of native Australian essential oils. The firm offers various products, including Essential Oil blends, Botanical Raw Honey collection, Raw Honey Probiotic Concentrate Tea Tree, and others. The company operates in markets across Australia and New Zealand, Asia Pacific, and North America.

Frequently asked questions about Eve Health Group

Converted at the current exchange rate, the Eve Health Group share trades at 0.01 EUR (0.01 AUD).

The revenue of Eve Health Group is 1.15 M AUD. This figure is based on current financial data and reflects the company's business performance.

The profit of Eve Health Group is -1.89 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Eve Health Group is currently -2.55. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Eve Health Group stock.

The price-to-sales ratio (P/S) of Eve Health Group is currently 4.18. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Eve Health Group stock.

The Eulerpool Quality Score for Eve Health Group is 3/10.

The ISIN of Eve Health Group is AU000000EVE3. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Eve Health Group is EVE.AX. The ticker symbol is used to trade Eve Health Group shares on the stock exchange.

Fair ValueTerminal
0.01 AUD
Over-/UndervaluationTerminal
Fairly valued
Industry
Food Products
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Australia
Currency
AUD
Initial public offering
Apr 8, 2004
ISIN
AU000000EVE3
Cusip
Q3658C112
Market capitalization
4.27 M AUDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
1.08
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-47.91 %
Last updated Oct 10, 2026, 5:41 AM

Eve Health Group Peer Group

Eve Health Group FIGI

EVE:AU · BBG000L8XCS5EVE:AT · BBG000L8XDN8EVE:AH · BBG002F3JYG0